MarketCapExport financials
China SXT Pharmaceuticals (SXTC)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
China SXT Pharmaceuticals Financial Ratios 2026-2011 | SXTC
Brief overview of China SXT Pharmaceuticals's financial ratios
Current figures are compared with the company's own five-year history for 2021–2025.
Market valuation is represented by EV/EBITDA 3.7x (median 2.45x), P/S 1.3x (median 0.06x), P/B 0.15x (median 0.01x). Valuation is 898.7% above five-year reference levels. The premium requires support from earnings and returns.
End-period return metrics are ROE -21.4%, ROA -15.2%, ROCE -17.1%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.
The cash cycle changed only slightly and ended at 166 days.
Valuation takeaway
China SXT Pharmaceuticals's multiples are demanding relative to current business quality. Material improvement is needed to justify them.
Annual Financial Ratios China SXT Pharmaceuticals
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.2 | -0.0 | -0.0 | -0.0 | -0.0 | -0.2 | -0.0 | 11.0 | 2.5 | - | - | - | - | - | - | - |
P/S |
1.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 2.4 | 0.4 | - | - | - | - | - | - | - |
EPS |
-9.1 | -348.2 | -4285.7 | -177.8 | -137.9 | -3.8 | 33.3 | 0.1 | 0.1 | 0.1 | - | - | - | - | - | - |
EV (Enterprise Value) |
-22 M | -11.9 M | -2.88 M | -2.5 M | 17.1 M | 5.69 M | 5.42 M | 14.1 M | 6.71 M | 3.51 M | - | - | - | - | - | - |
EBITDA per Share |
-10.4 | -274 | -3.2 K | -161 | -117 | -2.57 | -3.27 | 0.38 | 0.09 | - | - | - | - | - | - | - |
EV/EBITDA |
3.1 | 4.6 | 1.2 | 0.5 | -3.5 | -2.8 | -1.6 | 50.5 | - | - | - | - | - | - | - | - |
PEG |
-0.0 | -0.0 | -0.0 | -0.0 | - | - | 0.0 | 1.4 | - | - | - | - | - | - | - | - |
P/B |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.5 | 0.9 | - | - | - | - | - | - | - |
P/CF |
-0.3 | -0.0 | -0.0 | -0.1 | 0.0 | -0.4 | 0.4 | 70.5 | 1.6 | - | - | - | - | - | - | - |
ROE % |
-20.89 | -21.40 | -22.24 | -40.40 | -35.67 | -17.22 | -109.43 | 13.86 | 36.14 | - | - | - | - | - | - | - |
ROA % |
-17.85 | -15.25 | -13.40 | -20.08 | -17.10 | -7.95 | -47.40 | 8.81 | 15.51 | - | - | - | - | - | - | - |
ROCE % |
-23.43 | -17.13 | -17.68 | -37.24 | -32.27 | -13.76 | -14.21 | 15.87 | 49.68 | - | - | - | - | - | - | - |
Current Ratio |
6.9 | 3.5 | 2.5 | 2.0 | 2.0 | 1.9 | 1.8 | 2.7 | 1.8 | - | - | - | - | - | - | - |
DSO |
358.1 | 274.2 | 251.7 | 433.0 | 549.8 | 318.1 | 282.8 | 108.8 | - | - | - | - | - | - | - | - |
DIO |
329.4 | 215.6 | 176.1 | 182.9 | 253.7 | 165.0 | 141.1 | 76.6 | - | - | - | - | - | - | - | - |
DPO |
339.8 | 323.9 | 352.8 | 337.7 | 397.1 | 319.9 | 269.2 | 128.1 | - | - | - | - | - | - | - | - |
Operating Cycle |
687.5 | 489.9 | 427.7 | 615.9 | 803.5 | 483.1 | 423.9 | 185.4 | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
347.6 | 166.0 | 74.9 | 278.1 | 406.4 | 163.2 | 154.7 | 57.3 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios China SXT Pharmaceuticals
| 2026-Q4 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | -0.06 | -9.13 | - | -0.25 | -348.17 | - | -19.34 | -4285.66 | - | -0.584 | -177.837 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | -0.05 | -10.4 | - | -0.18 | -0.27 | - | -18.4 | -3.2 K | - | -0.41 | -161 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-57.70 | -79.10 | -238.63 | -217.74 | -239.98 | -244.68 | -223.29 | -263.68 | -22.24 | - | -10.04 | -40.40 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-44.61 | -59.86 | -102.16 | -84.31 | -97.70 | -101.85 | -86.60 | -106.68 | -13.40 | - | -6.74 | -20.08 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-58.68 | -75.80 | -218.24 | -194.81 | -212.49 | -216.05 | -198.93 | -236.17 | -17.68 | - | -7.73 | -37.24 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
3.5 | 4.3 | 6.9 | 2.5 | 1.9 | 3.5 | 2.0 | 1.5 | 2.5 | 2.0 | 3.0 | 2.0 | - | - | - | 2.0 | - | 2.5 | - | 1.9 | - | 4.3 | - | 1.8 | - | 2.0 | - | 2.8 | - | - | - | 1.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | 165.1 | 90.1 | - | 163.1 | 69.3 | - | 127.5 | 68.5 | - | 76.5 | 31.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | 132.9 | 80.6 | - | 111.3 | 45.1 | - | 90.2 | 60.2 | - | 47.3 | 15.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | 89.4 | 91.2 | - | 185.3 | 84.2 | - | 181.8 | 91.7 | - | 119.9 | 40.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | 112.3 | - | - | 94.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | 30.2 | - | - | 0.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company China SXT Pharmaceuticals, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Danmark
China
Britain
Australia
Israel
Germany
Canada
